Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins
- PMID: 29278833
- DOI: 10.1016/j.copbio.2017.12.016
Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins
Abstract
The subcutaneous administration of recombinant therapeutic proteins requires the use of highly concentrated protein formulations to provide the desired dosage in a single injection. These highly concentrated formulations can have very high viscosities, creating challenges in processing (e.g. by ultrafiltration), storage (e.g. enhanced aggregation), and delivery (e.g. injection through small bore needles). Recent work has begun to identify the key intermolecular interactions governing the behavior of these highly concentrated formulations, including the effects of different excipients that have been shown to reduce viscosity and enhance the stability of these formulations. These intermolecular interactions also have a significant effect on the filtrate flux and maximum achievable protein concentration that can be obtained during ultrafiltration used for final concentration and formulation of these therapeutic proteins.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: Effects of physical properties.Biotechnol Bioeng. 2017 Sep;114(9):2057-2065. doi: 10.1002/bit.26326. Epub 2017 May 18. Biotechnol Bioeng. 2017. PMID: 28464237
-
Ultrafiltration of highly concentrated antibody solutions: Experiments and modeling for the effects of module and buffer conditions.Biotechnol Prog. 2016 May;32(3):692-701. doi: 10.1002/btpr.2252. Epub 2016 May 17. Biotechnol Prog. 2016. PMID: 26918655
-
Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.Biotechnol Bioeng. 2017 Sep;114(9):2043-2056. doi: 10.1002/bit.26329. Epub 2017 May 26. Biotechnol Bioeng. 2017. PMID: 28464235 Free PMC article.
-
Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.Biotechnol Bioeng. 2020 Nov;117(11):3591-3606. doi: 10.1002/bit.27510. Epub 2020 Aug 3. Biotechnol Bioeng. 2020. PMID: 32687221 Review.
-
Viscosity of concentrated therapeutic protein compositions.Adv Drug Deliv Rev. 2011 Oct;63(13):1107-17. doi: 10.1016/j.addr.2011.09.008. Adv Drug Deliv Rev. 2011. PMID: 22014592 Review.
Cited by
-
A Reappraisal of Sedimentation Nonideality Coefficients for the Analysis of Weak Interactions of Therapeutic Proteins.AAPS J. 2019 Feb 27;21(3):35. doi: 10.1208/s12248-019-0307-0. AAPS J. 2019. PMID: 30815745 Free PMC article.
-
Harnessing ceramic hydroxyapatite as an effective polishing strategy to remove product- and process-related impurities in bispecific antibody purification.Bioresour Bioprocess. 2023 Dec 13;10(1):93. doi: 10.1186/s40643-023-00713-9. Bioresour Bioprocess. 2023. PMID: 38647984 Free PMC article.
-
The origins of nonideality exhibited by monoclonal antibodies and Fab fragments in human serum.Protein Sci. 2023 Dec;32(12):e4812. doi: 10.1002/pro.4812. Protein Sci. 2023. PMID: 37861473 Free PMC article.
-
Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume.MAbs. 2023 Jan-Dec;15(1):2285277. doi: 10.1080/19420862.2023.2285277. Epub 2023 Nov 27. MAbs. 2023. PMID: 38013454 Free PMC article. Review.
-
Comparison of Huggins Coefficients and Osmotic Second Virial Coefficients of Buffered Solutions of Monoclonal Antibodies.Polymers (Basel). 2021 Feb 17;13(4):601. doi: 10.3390/polym13040601. Polymers (Basel). 2021. PMID: 33671342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources